BeyondSpring, Inc. Banner Image

BeyondSpring, Inc.

  • Ticker BYSI
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
BeyondSpring, Inc. Logo Image
  • 51-200 Employees
  • Based in New York City, New York
BeyondSpring is a global, clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to improve clinical outcomes for patients with high unmet medical needs. BeyondSpring’s first-in-class lead immune asset, Plinabulin, is a potent antigen-presenting cell (APC) inducer. It is currently in two Phase 3 clinical trials for two severely unmet medicalMore needs indications: one is for the prevention of chemotherapy-induced neutropenia (CIN), the most frequent cause for a chemotherapy regimen dose’s decrease, delay, downgrade or discontinuation, which can lead to suboptimal clinical outcomes. The other is for non-small cell lung cancer (NSCLC) treatment in EGFR wild-type patients. As a “pipeline drug,” Plinabulin is in various I/O combination studies to boost PD-1 / PD-L1 antibody anti-cancer effects. In addition to Plinabulin, BeyondSpring’s extensive pipeline includes three pre-clinical immuno-oncology assets and a drug discovery platform dubbed “molecular glue” that uses the protein degradation pathway.
4.8 / 5.0 (142)

BeyondSpring, Inc. reports have an aggregate usefulness score of 4.8 based on 142 reviews.

BeyondSpring, Inc.

Most Recent Annual Report

BeyondSpring, Inc.
MOST RECENT 2022 Annual Report

Older/Archived Annual Reports

BeyondSpring, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!